AVONEX (Interferon beta-1a) is a leading therapeutic for relapsing forms of MS to slow the progression of disability and reduce relapses. AVONEX is also approved for patients who have their first clinical MS attack and have a brain MRI scan consistent with MS.

TYSABRI is being developed and co-marketed under a collaboration agreement with Elan.

TYSABRI is being developed and co-marketed under a collaboration agreement with Elan.

RITUXAN is being developed and co-marketed under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group.

RITUXAN (Rituximab) is in development for the treatment of ANCA Associated Vasculitis, and is not currently approved for this indication. RITUXAN is being developed and co-marketed under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group.

RITUXAN is being developed and co-marketed under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group.

RITUXAN is being developed and co-marketed under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group.

FUMADERM is an oral product containing fumaric acid esters, and was approved in Germany in 1994 for treatment of severe psoriasis. Acquired with the Fumapharm purchase.

FAMPYRA is an investigational oral, prolonged-release formulation of 4-aminopyridine, that has been developed to improve walking ability in adult patients with multiple sclerosis (MS). Studies have shown that fampridine can increase conduction velocity along damaged nerves, which may result in improved neurological function. This compound is approved in the US (where it is known as AMPYRA) and is being commercialized outside of the US by Biogen Idec under a licensing agreement with Acorda Therapeutics.

Small molecule immune modulator, oral formation. Acquired with Fumapharm purchase.

PEGylated Interferon beta-1a is a chemically modified version of interferon beta-1a, designed to increase half-life and systemic exposure of the protein.

Humanized antibody specific for IL2 receptor. Daclizumab is being developed under a collaboration agreement with Abbott Biotherapeutics.

Long-lasting factor IX fusion protein for the treatment of hemophilia B. Acquired with Syntonix transaction. Biogen Idec and Swedish Orphan Biovitrum are working in collaboration on co-development.

Long-lasting factor VIII fusion protein for the treatment of hemophilia A. Acquired with Syntonix transaction. Biogen Idec and Swedish Orphan Biovitrum are working in collaboration on co-development.

Humanized monoclonal antibody specific for CD20. Humanized anti-CD20 mAb is being developed under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group.

Humanized monoclonal antibody specific for CD20. Humanized anti-CD20 mAb is being developed under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group.

Novel oral neuroprotective therapy. Dexpramipexole is being developed under a licensing agreement with Knopp Biosciences.

Humanized monoclonal antibody specific for CD20. Humanized anti-CD20 mAb is being developed under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group.

Humanized monoclonal antibody specific for TWEAK.

Anti-LINGO 1 is being investigated for use in multiple sclerosis.

Neublastin is being investigated for use in neuropathic pain.

CD40L is being investigated for use in systemic lupus erythematosus.

BART is being investigated for use in Alzheimer's disease.